Search clinical trials for: naquotinib mesilate

Total 1385 results

Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Astellas Pharma Global Development, Inc.

Withdrawn

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors

Solid Tumors | Epidermal Growth Factor Receptor (EGFR) Mutations
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor (EGFR) Mutations

United States
Eisai Limited

Completed

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Solid Tumors

United Kingdom
Astellas Pharma Global Development, Inc.

Withdrawn

A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study

Subjects With NSCLC With an EGFR Activating Mutation
University of Bologna

Completed

Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase

Myeloid Leukemia, Chronic, Chronic-Phase

Italy
Astellas Pharma Inc

Terminated

An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer

Japan, Korea, Republic of, Taiwan
Novartis Pharmaceuticals

Completed

Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

Refractory Desmoplastic Small Round Cell Tumors

Italy
Astellas Pharma Global Development, Inc.

Completed

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Small-Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor Mutations

United States
Astellas Pharma Inc

Terminated

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

Japan
Chengdu Zenitar Biomedical Technology Co., Ltd

Completed

Study of Prilinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Diffuse Large B Cell Lymphoma，DLBCL

China
Centre Leon Berard

Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)

Gastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene Mutation

France
Swiss Group for Clinical Cancer Research

Terminated

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Adenocarcinoma | Breast Cancer

Switzerland
Tianjin Chasesun Pharmaceutical Co., LTD
Southwest Hospital, China

Completed

Phase I Study of Kukoamine B Mesilate in Healthy Volunteers

Healthy

China
Cancer Research UK
Latus Therapeutics

Terminated

A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) (SPIKE-1)

COVID-19 Infection

United Kingdom
IlDong Pharmaceutical Co Ltd

Completed

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer (PDF inhibitor)

Healthy

Korea, Republic of
Sagent Pharmaceuticals Inc.

Completed

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

COVID-19

United States
Chengdu Zenitar Biomedical Technology Co., Ltd

Not yet recruiting

A Clinical Study of Puesta Mesylate for Injection in Patients With Solid Tumors

Advanced Solid Tumor

China
Yale University

Completed

Camostat Mesylate in COVID-19 Outpatients

COVID-19

United States
Tianjin Chasesun Pharmaceutical Co., LTD
Southwest Hospital, China

Completed

Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers

Healthy

China
Eisai Inc.

Completed

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Breast Cancer

United States
Eisai Co., Ltd.

Completed

Study of E7389 for Advanced or Metastatic Breast Cancer

Breast Cancer

Japan
Nanjing First Hospital, Nanjing Medical University

Enrolling by invitation

Mid-and Long-term Efficacy of Ergot Alkaloids in the Treatment of Salivation in Patients With Parkinson's Disease.

Main Heading (Descriptor) Terms

China
Eisai Limited

Completed

QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

France
Calgent Biotechnology Co., Ltd

Completed

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Resistant or Refractory Solid Tumors

United States, Taiwan
Eisai Korea Inc.

Completed

Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (ESKIMO)

Breast Cancer | Breast Neoplasms

Korea, Republic of
Eisai Inc.

Approved for marketing

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Metastatic Breast Cancer

Canada, Belgium, France
Merz Pharmaceuticals GmbH

Terminated

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus (OLLTT)

Subjective Tinnitus

United States, United Kingdom, Poland, Austria, Belgium, Brazil, Czech Republic, France, Germany, Mexico, Netherlands, Portugal, South Africa, Spain
Pathway Therapeutics, Inc.

Completed

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

Malignancies

United States
Merz Pharmaceuticals GmbH

Terminated

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Multiple Sclerosis | Nystagmus, Congenital | Nystagmus, Acquired

United Kingdom
Merz Pharmaceuticals GmbH

Completed

Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

Healthy

Germany
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Eisai Inc.

Completed

A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

India
Eisai Inc.
Children's Oncology Group

Completed

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas (BOLD 113)

Solid Tumors | Pediatrics

United States
Chang Gung Memorial Hospital
Eisai Co., Ltd.; Kaohsiung Breast Cancer Prevention and Education Society (KBCPES)

Unknown

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

Advanced Breast Cancer | Metastatic Breast Cancer

Taiwan
Eisai Co., Ltd.

Completed

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Soft Tissue Sarcoma

Japan
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus (EASE)

Subjective Tinnitus

Germany, Portugal, Spain, United Kingdom, Austria
Eisai Inc.

Completed

Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System

Cancer

Netherlands
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients (EMBRAVE-001)

Triple Negative Breast Cancer

China
National Cancer Institute (NCI)

Completed

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

Subjective Tinnitus

United States, Austria, Germany, Brazil, Mexico
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus

Subjective Tinnitus

Belgium, Czech Republic, France, Poland, South Africa, Netherlands
Hunan Cancer Hospital

Completed

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Metastatic Breast Cancer

China
Oncologia Medica dell'Ospedale Fatebenefratelli
Mario Negri Institute for Pharmacological Research

Completed

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Metastatic Breast Cancer | Toxicity | Neurotoxicity | Adverse Drug Event | Drug Toxicity

Italy
Seoul National University Hospital

Recruiting

Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer (ESPERO)

Advanced Breast Cancer

Korea, Republic of
Bausch & Lomb Incorporated

Completed

Safety, Pharmacokinetics, and Efficacy of Bepotastine Besilate Nasal Product After Ragweed Pollen Exposure in an Environmental Chamber

Seasonal Allergic Rhinitis

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials

Solid Tumors

United States, China, Belgium, Australia, Italy, Korea, Republic of, Germany, Netherlands, Poland, Romania, Thailand
InteKrin Therapeutics, Inc.

Completed

A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States

3

Subscribe